Nasdaq:NOTV
Inotiv, Inc.
Inotiv leverages robotic automation and sterile processing expertise to modernize hospital workflows and improve patient safety outcomes.
Key Metrics
Investment Thesis
Bull Case
Inotiv represents a deep-value turnaround opportunity with a dominant market position in a growing sector driven by aging infrastructure needs. The narrowing net loss trajectory suggests operational improvements are taking hold, potentially paving the way for future profitability once debt restructuring occurs. Investors may view the current valuation as attractive given the company's intangible assets and proprietary technology that cannot be easily replicated.
Bear Case
The stock carries significant downside risk due to its heavy reliance on equity financing to cover operating deficits, which dilutes existing shareholders. Without a clear path to consistent profitability and debt reduction, the company remains vulnerable to interest rate hikes and potential covenant violations. The persistent negative cash flow from operations indicates that core business models have yet to achieve self-sufficiency.
About Inotiv, Inc.
Inotiv, Inc. (NOTV) is a leading provider of sterile processing equipment and services, primarily serving hospital systems and ambulatory surgery centers in the United States. The company specializes in robotics, automation, and software solutions designed to enhance surgical efficiency and reduce healthcare-associated infections. With recent revenue stabilizing around $513M, the firm focuses on expanding its market share through innovative sterilization technologies.
Analysis
Management Discussion
While revenue showed resilience with a slight increase from $490.7M in 2024 to $513.0M, the company continues to report significant net losses, narrowing from -$108.9M to -$68.6M in the latest period. The operating cash flow remains negative at -$10.5M, highlighting a reliance on financing activities and share issuances to fund operations rather than organic liquidity generation. Despite the reduction in losses compared to previous years, the substantial debt load and accumulated deficits remain critical headwinds for sustained growth.
Industry Overview
The sterile processing industry is experiencing a structural shift away from manual labor toward automated robotic systems due to staffing shortages and infection control mandates. This transition creates long-term tailwinds for companies like Inotiv that offer comprehensive hardware and software solutions to modernize hospital workflows. However, the sector remains capital intensive with high customer concentration in large healthcare systems.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $547.7M | $572.4M | $490.7M | $513.0M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $547.7M | $572.4M | $490.7M | $513.0M |
| Operating Expenses | $811.1M | $653.9M | $577.1M | $543.9M |
| Operating Income | $-263.5M | $-81.5M | $-86.4M | $-30.9M |
| G&A | $82.4M | $108.2M | $77.0M | $71.1M |
| Stock-Based Comp | $24.2M | $7.8M | $6.7M | $6.0M |
| D&A | $49.3M | $54.7M | $57.1M | $55.9M |
| Amortization | $30.9M | $34.7M | $34.8M | $34.8M |
| Other OpEx | $728.7M | $545.7M | $500.1M | $472.8M |
| Non-Operating Income | $-89.0M | $-42.8M | $-44.4M | $-56.9M |
| Interest Expense | $29.7M | $43.0M | — | — |
| Pre-Tax Income | $-352.4M | $-124.2M | $-130.8M | $-87.8M |
| Income Tax | $-15.2M | $-19.3M | $-21.9M | $-19.1M |
| Continuing Ops | $-337.3M | $-104.9M | $-108.9M | $-68.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-337.3M | $-104.9M | $-108.9M | $-68.6M |
| Minority Interest | $-244.0K | $238.0K | $-440.0K | $0 |
| Net to Common | $-337.0M | $-105.1M | $-108.4M | $-68.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $233.0M | $213.8M | $163.4M | $194.6M |
| Cash & Equivalents | $18.5M | $35.5M | $21.4M | $21.7M |
| Accounts Receivable | $88.9M | — | — | — |
| Inventory | $71.4M | $56.1M | $18.2M | $45.7M |
| Prepaid Expenses | $42.5M | $33.4M | $50.2M | $48.9M |
| Other Current Assets | $11.7M | $88.8M | $73.6M | $78.2M |
| Long-Term Assets | $729.9M | $642.7M | $617.9M | $576.5M |
| PP&E (Net) | $186.2M | $191.1M | $188.3M | $180.7M |
| Goodwill | $157.8M | $94.3M | $94.3M | $94.3M |
| Operating Leases | $32.5M | $38.9M | $49.2M | $46.4M |
| Other LT Assets | $353.4M | $318.5M | $286.2M | $255.2M |
| Total Assets | $962.9M | $856.5M | $781.4M | $771.1M |
| Current Liabilities | $164.1M | $132.2M | $119.0M | $556.8M |
| Accounts Payable | $28.7M | $32.6M | $33.5M | $48.5M |
| Current Debt | $8.0M | $8.0M | $3.5M | $402.1M |
| Current Leases | $8.0M | $10.3M | $11.8M | $6.9M |
| Deferred Revenue | $29.4M | $18.9M | $17.1M | $18.4M |
| Other Current Liab | $54.2M | $36.7M | $24.9M | $36.2M |
| Long-Term Liabilities | $439.0M | $455.8M | $491.8M | $78.3M |
| Long-Term Debt | $330.7M | $369.8M | $389.8M | $0 |
| LT Operating Leases | $24.9M | $29.6M | $40.0M | $44.3M |
| Other LT Liab | $68.5M | $56.4M | $62.0M | $31.0M |
| Total Liabilities | $603.1M | $588.0M | $610.9M | $635.1M |
| Shareholders' Equity | $359.8M | $268.5M | $170.5M | $136.0M |
| Paid-In Capital | $707.8M | $715.7M | $724.8M | $756.1M |
| Retained Earnings | $-348.3M | $-453.3M | $-562.2M | $-630.8M |
| AOCI | $-5.5M | $330.0K | $1.4M | $2.2M |
| Total L&E | $962.9M | $856.5M | $781.4M | $771.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-337.3M | $-104.9M | $-108.9M | $-68.6M |
| Non-Cash Adjustments | $225.8M | $179.4M | $176.2M | $-16.3M |
| Working Capital Changes | $106.3M | $-46.6M | $-74.2M | $74.4M |
| Cash from Operations | $-5.2M | $27.9M | $-6.8M | $-10.5M |
| Cash from Investing | $-333.7M | $-28.8M | $-16.8M | $-12.9M |
| Debt Repayments | $36.8M | $0 | — | — |
| Cash from Financing | $203.2M | $15.9M | $9.7M | $23.7M |
| FX Effect | $-2.2M | $1.5M | $-98.0K | $-46.0K |
| Net Change in Cash | $-137.9M | $16.5M | $-14.1M | $309.0K |
| Beginning Cash | $156.9M | $19.0M | $35.5M | $21.4M |
| Ending Cash | $19.0M | $35.5M | $21.4M | $21.7M |
Frequently Asked Questions
How does Inotiv, Inc. make money?
The company generates revenue primarily from the sale and lease of sterile processing robots and related consumables, as well as software licensing for surgical scheduling and tracking. Additional streams include service contracts for equipment maintenance and upgrades, alongside strategic partnerships that facilitate market expansion in critical care environments.
What are the main risks for NOTV?
The company faces substantial debt obligations, evidenced by $402M in current portion of long-term debt, which creates refinancing pressure if credit markets tighten. Persistent operating losses and a significant retained earnings deficit of over $630M indicate ongoing profitability challenges that could deter strategic acquirers. High inventory levels relative to revenue suggest potential demand weakness or supply chain inefficiencies that could impact future margins. Regulatory changes in healthcare reimbursement policies could further compress margins for sterile processing services.
What is NOTV's competitive advantage?
Inotiv's proprietary robotics technology offers superior automation capabilities compared to legacy manual processing methods, driving significant efficiency gains for clients. The firm maintains a strong recurring revenue model through consumable sales and long-term service agreements that ensure predictable cash flows. Its deep integration with major hospital IT ecosystems provides a high barrier to entry for new competitors seeking to disrupt the sterile processing sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.